[Reversible alterations in the dentate nuclei and rapid-onset cerebral atrophy due to neurotoxicity caused by lithium]. / Alteraciones reversibles en los nucleos dentados y atrofia cerebral de rapida instauracion debido a neurotoxicidad por litio.

INTRODUCTION: Treatment with lithium can cause several neurological side effects, even at therapeutic levels. CASE REPORT: We report the case of a 49-year-old woman, with bipolar disorder and depression, undergoing treatment with lithium, antidepressants and antipsychotics, who was admitted to hospital due to a clinical picture of visual hallucinations with an elevated lithaemia of 2.1 mEq/L (therapeutic range: 0.6-1.2 mEq/L). The patient developed a severe encephalopathy that required the use of assisted ventilation in the intensive care unit. Initial magnetic resonance imaging showed a reversible bilateral symmetrical hyperintensity in the dentate nuclei in T2 and T2-FLAIR sequences. Over the following months she gradually developed a pancerebellar syndrome with evidence of a marked loss of bilateral volume in the cerebellum, above all at the expense of the vermis, which was accompanied by a permanent and disabling cerebellar syndrome. CONCLUSIONS: Although treatment with lithium can cause a variety of neurological side effects, they are usually reversible. However, they occasionally give rise to permanent and disabling sequelae, as in the case of the patient reported here, with a marked and progressive cerebellar atrophy, accompanied by permanent sequelae in the form of a disabling cerebellar syndrome. The cerebellar neurotoxicity of lithium must be taken into account in the broad differential diagnosis of cerebellar ataxia in adults.

TITLE: Alteraciones reversibles en los nucleos dentados y atrofia cerebral de rapida instauracion debido a neurotoxicidad por litio.Introduccion. El tratamiento con litio puede ocasionar diversos efectos adversos neurologicos, incluso con niveles terapeuticos. Caso clinico. Mujer de 49 años, con trastorno bipolar y depresion, en tratamiento con litio, antidepresivos y antipsicoticos, que ingreso por un cuadro de alucinaciones visuales con una litemia elevada de 2,1 mEq/L (rango terapeutico: 0,6-1,2 mEq/L). Progreso a una encefalopatia grave que requirio asistencia respiratoria en la unidad de cuidados intensivos. La resonancia magnetica cerebral inicial mostro una hiperintensidad simetrica bilateral reversible en los nucleos dentados en las secuencias T2 y T2-FLAIR. A lo largo de los meses posteriores desarrollo de forma progresiva un sindrome pancerebeloso con evidencia de una marcada perdida de volumen bilateral en el cerebelo, sobre todo a expensas del vermis, que se acompaño clinicamente de un sindrome cerebeloso permanente e invalidante. Conclusiones. Aunque el tratamiento con litio ocasiona efectos adversos neurologicos variados, estos suelen ser reversibles. Puede dar lugar a secuelas permanentes e incapacitantes, como la paciente descrita, con una atrofia cerebelosa marcada y progresiva, acompañada de secuelas permanentes en forma de sindrome cerebeloso invalidante. La neurotoxicidad cerebelosa del litio debe considerarse en el amplio diagnostico diferencial que representa la ataxia cerebelosa del adulto.

The effect of partial substitution of Ni by Mg on the structural, magnetic and spectroscopic properties of the double perovskite Sr2NiTeO6.

In this report, the structural, magnetic and spectroscopic properties of the freeze-drying synthesized Sr2Ni1-xMgxTeO6 (x = 0.0, 0.1, 0.2, 0.3 and 0.5) oxides are analyzed by means of X-ray powder diffraction (XRPD) and neutron powder diffraction (NPD), electron paramagnetic resonance, diffuse reflectance and magnetic susceptibility. The XRPD and NPD data analysis using the mode-crystallography approach have revealed that at room temperature (RT), all the compositions are monoclinically distorted with the space group I2/m. The high and low temperature analyses have shown that these materials suffer a series of three structural phase transitions. The EPR results have shown that the spectra of all the compositions are centred at g≈ 2.28, indicating a slightly distorted octahedral environment of Ni(2+), which is in agreement with the crystal structure analysis. The increase of the Mg(2+) content in Sr2Ni1-xMgxTeO6, provokes a decrease of the dipolar interaction effects and thus, the resonance becomes narrower. This resonance does not completely disappear which leads to the idea that the long-range magnetic order is not completely established when x≥ 0.3. The substitution of the Ni(2+) (S = 1) ions by Mg(2+) (S = 0) ions, also induces a weakening of the antiferromagnetic interactions, which is reflected in the diminishing of the absolute value of θ and the Néel temperature TN. The magnetic structure determination revealed the existence of an antiferromagnetic coupling for x- and z-spin components of the nickel atoms.

Synthesis, structural, magnetic and phase-transition studies of the ferromagnetic La2CoMnO6 double perovskite by symmetry-adapted modes.

A powdered La2CoMnO6 double perovskite was synthesized by the solid-state reaction method, and its crystal structure was investigated by (mode-crystallography) Rietveld analysis using X-ray and neutron powder diffraction data. La2CoMnO6 material is a monoclinic perovskite at room temperature, adopting the space group P21/n (a(-)a(-)b(+)), , c ≈ 2ap and Z = 2. The P21/n phase can be described effectively by three distortion modes (GM4(+), X3(+), X5(+)) of the Fm3[combining macron]m (a(0)a(0)a(0)) parent phase. The comparative study of the material and those in the Ln2CoMnO6 and Ln2NiMnO6 families has shown a general trend in nearly all the materials, has served to select a common direction in the sub-space spanned by X5(+), tri-linearly coupled to the order parameters of the cubic to monoclinic first order phase transition. This direction has been used to parametrize the refinements and to perform reliable refinements in the high-temperature intermediate distorted trigonal phase, R3[combining macron] (a(-)a(-)a(-)), for which only one effectively acting irrep has been deduced: GM5(+), physically a tilt of the oxygen sharing octahedra of Co and Mn. Its temperature evolution up to the prototype cubic phase has been fitted in the framework of the Landau Theory of Phase Transitions, showing a behavior typical of a tricritical point. The low-temperature neutron powder diffraction data have served to solve the magnetic structure: three indistinguishable ferromagnetic models with the space groups P21/n and P2/n' are proposed.

Structural phase transitions and magnetic and spectroscopic properties of the double perovskites Sr2Co1-xMgxTeO6 (x = 0.1, 0.2 and 0.5).

The structural and magnetic properties of a series of ordered double perovskites with the formula Sr(2)Co(1-x)Mg(x)TeO(6) (x = 0.1, 0.2 and 0.5) are investigated by X-ray diffraction, low temperature neutron diffraction, electron paramagnetic resonance and magnetic susceptibility. The progressive substitution of the paramagnetic Co(2+) high spin ion by the diamagnetic Mg(2+), of about the same size, induces changes in the room temperature crystal structure, from a distorted P2(1)/n phase for the undoped Sr(2)CoTeO(6) oxide to the I4/m of the end member (Sr(2)MgTeO(6)). These perovskites experience structural transitions on heating, the temperature at which the transitions occur being smaller as x increases. The novel approach of mode-crystallography is used for the analysis. All oxides show antiferromagnetic exchange interactions between Co(2+) ions but the long range antiferromagnetic order is not achieved for the phase with x = 0.5. The low temperature neutron diffraction data have been evaluated using a full symmetry analysis. Results are consistent with an unquenched orbital contribution of a high spin Co(2+) ion.

Complicación espinal hemorrágica secundaria a una punción lumbar diagnóstica. Respuesta / Spinal cord hemorrhage complicating diagnostic lumbar puncture. Reply

No disponible

No disponible

The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.

INTRODUCTION: In 1981, Dr. PH Sugarbaker, challenging oncological orthodoxy, considered carcinomatosis to be a locoregional stage of the disease that was still susceptible to treatment with curative intent. To this end he developed a new therapeutic alternative based on the combined treatment. The macroscopic disease treated by maximum radical oncological cytoreductive surgery (through the peritonectomies described by him), followed by treatment of the residual microscopic disease with the direct intra-abdominal application of intraoperative chemotherapy with locoregional intensification, modulated by hyperthermia and early normothermic postoperative intra-abdominal chemotherapy. Using this new therapeutic regimen, known as "Sugarbaker s Protocol", his group has reported 45% survival rates in carcinomatosis of colorectal origin at 5 years, and, in selected groups of patients, 50% survival rates at 5 years. The scientific community, however, has criticized these results considering that: it is a personal experience, with a not homogenous treatment protocol with developmental modifications over time, that it is a retrospective non-randomized study, and finally that the cytostatics used in his protocol are obsolete. Various European groups have replied to these main criticisms confirming the good results that this new therapeutic alternative offers for patients with carcinomatosis of colorectal origin. The purpose of this article is to present these contributions. MATERIAL AND METHODS: All the articles published in the English language by European groups in the world s medical literature have been reviewed using the Pubmed-MEDLINE database to identify the relevant articles related to the treatment of carcinomatosis of colorectal origin using cytoreduction and intraperitoneal chemotherapy from January 1980 to January 2008. RESULTS: The European contribution during these 25 years in favour of the "Sugarbaker s Protocol" has consisted fundamentally in: a) one multicenter retrospective study; b) two randomized prospective phase III studies; and c) the use of oxaliplatin and irinotecan as new cytostatic agents in the protocols for intraperitoneal chemotherapy. At the same time, two new transcendental European contributions have been made in which the possibility has been considered of combined simultaneous treatment for patients with hepatic metastases and carcinomatosis, and the introduction, as a selection factor, of patients responsive to intravenous induction chemotherapy within the regimen of sandwich treatment (with systemic neoadjuvant and adjuvant chemotherapy) complementary to intraperitoneal chemotherapy. CONCLUSIONS: The results obtained by European groups using "Sugarbaker s protocol" and "Elias protocol" with oxaliplatin compel us to request that these treatments be considered by all professionals involved in the treatment of patients with colorectal carcinomatosis as the best treatment currently available for this condition. Furthermore a randomized, prospective, multicenter study should be carried out to clarify its value and the degree of scientific evidence. A validation of this treatment will change, in the future, the dogmatic consideration of carcinomatosis as an incurable disease stage.

[Spinal cord hemorrhage complicating diagnostic lumbar puncture]. / Complicación espinal hemorrágica secundaria a una punción lumbar diagnóstica.

INTRODUCTION: Spinal cord hematoma is a serious and feared complication of lumbar puncture. We here describe two patients who developed a spinal cord hematoma following diagnostic lumbar punctures. CASE REPORTS: CASE 1: a 22-year-old male with a syndrome of cerebrospinal fluid hypotension, with normal coagulation parameters, underwent a traumatic, diagnostic lumbar puncture followed, a few hours later, by back pain irradiated to the legs. MRI showed the presence of a subdural hematoma from the lower dorsal region to the sacral region. A conservative approach, without surgery, was decided and he showed a complete recovery. CASE 2: a 69-year-old woman underwent a diagnostic lumbar puncture for the study of recent-onset headache with tinnitus and unstable gait. Puncture was traumatic and cerebrospinal fluid was normal. A few hours later, she complained of back pain and sciatica, and examination revealed a bilateral Lassegue sign. She required urinary catheterization. MRI showed an epidural hematoma from the T10 vertebra to the sacral area. Her outcome with a conservative approach was also excellent. CONCLUSIONS: Spinal cord hematomas can occur after a traumatic lumbar puncture in people without coagulation disorders or any other predisposing factor. Although surgery has been traditionally advocated in these cases, a conservative approach is an option when symptoms are mild and a close follow-up is possible.

Complicación espinal hemorrágica secundaria a una punción lumbar diagnóstica / Spinal cord hemorrhage complicating diagnostic lumbar puncture

Introducción. El hematoma espinal es una grave complicación de la punción lumbar. Se muestran los casos de dos pacientes que presentaron hematomas espinales tras la práctica de punciones lumbares diagnósticas. Casos clínicos. Caso 1. Varón de 22 años, con hipotensión de líquido cefalorraquídeo y estudio de coagulación normal. Se le realizó una punción lumbar que fue traumática y en las siguientes horas desarrolló dolor lumbar con irradiación radicular. En la resonancia magnética se detectó la existencia de un hematoma subdural desde la región dorsal baja hasta la región sacra. El tratamiento fue conservador, sin cirugía, con una excelente evolución. Caso 2. Mujer de 69 años a quien se le realizó una punción lumbar diagnóstica para el estudio de una cefalea de reciente comienzo con acúfenos e inestabilidad. La punción lumbar fue traumática, y se obtuvo un líquido cefalorraquídeo normal. Horas después presentó dolor lumbar con irradiación radicular. En la exploración se apreció un signo de Lassegue positivo y precisó sondaje urinario. En la resonancia magnética se observó un hematoma epidural desde D10 hasta la región sacra. Su evolución, tratada de forma conservadora, también fue satisfactoria. Conclusiones. Las punciones lumbares traumáticas favorecen el desarrollo de hemorragias espinales en pacientes sin coagulopatías u otros factores de predisposición. Aunque en estos casos se ha recomendado un tratamiento quirúrgico, la actitud terapéutica puede ser conservadora cuando el cuadro clínico sea menor y se garantice un estrecho seguimiento (AU)

Introduction. Spinal cord hematoma is a serious and feared complication of lumbar puncture. We here describe two patients who developed a spinal cord hematoma following diagnostic lumbar punctures. Case reports. Case 1: a 22-year-old male with a syndrome of cerebrospinal fluid hypotension, with normal coagulation parameters, underwent a traumatic, diagnostic lumbar puncture followed, a few hours later, by back pain irradiated to the legs. MRI showed the presence of a subdural hematoma from the lower dorsal region to the sacral region. A conservative approach, without surgery, was decided and he showed a complete recovery. Case 2: a 69-year-old woman underwent a diagnostic lumbar puncture for the study of recent-onset headache with tinnitus and unstable gait. Puncture was traumatic and cerebrospinal fluid was normal. A few hours later, she complained of back pain and sciatica, and examination revealed a bilateral Lassegue sign. She required urinary catheterization. MRI showed an epidural hematoma from the T10 vertebra to the sacral area. Her outcome with a conservative approach was also excellent. Conclusions. Spinal cord hematomas can occur after a traumatic lumbar puncture in people without coagulation disorders or any other predisposing factor. Although surgery has been traditionally advocated in these cases, a conservative approach is an option when symptoms are mild and a close follow-up is possible (AU)

Aportación europea al “protocolo de Sugarbaker” en el tratamiento de la carcinomatosis peritoneal colorrectal / The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis

Introducción: el Dr. P. H. Sugarbaker en 1981, desafiando la ortodoxia oncológica, consideró la carcinomatosis como un estadio locorregional de la enfermedad susceptible todavía de tratamiento con intención curativa. Para ello desarrolló una nueva alternativa terapéutica basada en el tratamiento combinado. La enfermedad macroscópica mediante la máxima cirugía citorreductora radical oncológica (merced a las peritonectomías por él descritas), seguido del tratamiento de la enfermedad microscópica residual con la aplicación directa intraabdominal, de quimioterapia de intensificación locorregional, intraoperatoria modulada por hipertermia y de quimioterapia intraabdominal normotérmica postoperatoria precoz. Con este nuevo esquema terapéutico, conocido como "Protocolo de Sugarbaker", su grupo ha publicado supervivencias en carcinomatosis de origen colorrectal de 45% a 5 años y en grupos selectos de pacientes supervivencia de 50% a 5 años. La comunidad científica, sin embargo, ha criticado estos resultados al considerar que: se trata de una experiencia personal, con un protocolo de tratamiento no homogéneo con modificaciones evolutivas en el tiempo, tratarse de un estudio retrospectivo no randomizado, y finalmente considerar que los citostáticos empleados en su protocolo son obsoletos. Diversos grupos europeos han dado respuesta a las principales objeciones, confirmando los buenos resultados que esta nueva alternativa terapéutica ofrece en pacientes con carcinomatosis de origen colorrectal. El objetivo de este trabajo es presentar estas aportaciones. Material y métodos: se han revisado todos los artículos publicados en lengua inglesa por grupos europeos en la literatura médica mundial usando la base de datos Pubmed-MEDLINE para identificar los artículos relevantes relacionados con el tratamiento de la carcinomatosis de origen colorrectal mediante citorreducción y quimioterapia intraperitoneal desde enero de 1980 a enero de 2008...(AU)

Introduction: in 1981, Dr. PH Sugarbaker, challenging oncological orthodoxy, considered carcinomatosis to be a locoregional stage of the disease that was still susceptible to treatment with curative intent. To this end he developed a new therapeutic alternative based on the combined treatment. The macroscopic disease treated by maximum radical oncological cytoreductive surgery (through the peritonectomies described by him), followed by treatment of the residual microscopic disease with the direct intra-abdominal application of intraoperative chemotherapy with locoregional intensification, modulated by hyperthermia and early normothermic postoperative intra-abdominal chemotherapy. Using this new therapeutic regimen, known as "Sugarbaker's Protocol", his group has reported 45% survival rates in carcinomatosis of colorectal origin at 5 years, and, in selected groups of patients, 50% survival rates at 5 years. The scientific community, however, has criticized these results considering that: it is a personal experience, with a not homogenous treatment protocol with developmental modifications over time, that it is a retrospective non-randomized study, and finally that the cytostatics used in his protocol are obsolete. Various European groups have replied to these main criticisms confirming the good results that this new therapeutic alternative offers for patients with carcinomatosis of colorectal origin. The purpose of this article is to present these contributions. Material and methods: all the articles published in the English language by European groups in the world's medical literature have been reviewed using the Pubmed-MEDLINE database to identify the relevant articles related to the treatment of carcinomatosis of colorectal origin using cytoreduction and intraperitoneal chemotherapy from January 1980 to January 2008...(AU)

Pseudomixoma peritoneal. Supervivencia superior a 10 años tras citorreducción, quimioterapia intraperitoneal e hipertermia / No disponible

No disponible

Prevalencia y tratamiento de la patología oncológica en el anciano. El reto que se avecina / No disponible

La esperanza media de vida en España se ha más que duplicadoa lo largo del siglo XX, llegando en la actualidad a 75 años enel varón y 83 años en la mujer. Las predicciones de la evolución ycrecimiento poblacional a nivel mundial y nacional auguran unshock demográfico cuando en España el número de mayores de65 años alcance el 33,5% de la población en el 2050.Es conocido que el cáncer está intrínseca y directamente relacionadocon la edad, siendo una patología de personas mayores,ya que al menos el 60% de ellos aparecen en mayores de 65años. Los ancianos constituyen el grupo más importante de lapráctica oncológica médica. Las predicciones de envejecimientode la población española, permiten intuir que el cáncer en el ancianoy su tratamiento deba ser considerado un problema sanitariode primer orden.El cáncer ya no es sinónimo de muerte para la mayoría de lospacientes. Globalmente el 60% se curan o cronifican. Esta mejorapronóstico tiene un precio tanto en las expectativas de tratamientocomo de posterior seguimiento y mantenimiento de las secuelasque pueden generarse.El mayor y mejor conocimiento y comprensión del proceso deenvejecimiento, permitirá identificar y seleccionar aquellos pacientesmayores que pueden beneficiarse de medidas de prevención ytratamiento, y lo más importante permitirá identificar aquellos pacientesque no son candidatos de tratamientos con intención curativapor tratarse de población frágil.Los adelantos en el campo de la cirugía, especialmente en lacirugía mínimamente invasiva y su aplicación al campo de la cirugíaoncológica, permiten prever que un mayor número de pacientesancianos podrán beneficiarse de un tratamiento con intencióncurativa. La edad no prevendrá de tratamientos apropiados en individuosancianos con cáncer, especialmente aquellos en los quetengan una adecuada expectativa de vida y reserva funcional.Combatir esta discriminación sanitaria constituye una de las principalesprioridades en la estrategia para el mantenimiento de lasalud del anciano. Presentamos y analizamos en este trabajo los cambios poblacionalesque se avecinan de forma particular en España, la vinculacióndel cáncer con la edad con sus particularidades específicas,los criterios generales de fragilidad del anciano, las limitacionesque la edad suponen para la aplicación de distintos tratamientosadyuvantes complementarios, y las nuevas alternativas quirúrgicasaplicables en pacientes oncológicos ancianos en los cánceres másfrecuentes de la práctica clínica

Life expectancy in Spain has more than duplicated during thelast 20th Century, and is currently 75 years for men and 83 yearsfor women. Predictions on the evolution of the National and globalpopulation anticipate a demographic shock in Spain when individualsolder than 65 years eventually make up more than 33.5%of the Spanish population by year 2050.It is known that cancer is directly related with age, and that itis a disease of older people –at least 60% of all cancers are diagnosedin patients older than 65 years. The older people group isthe most important group of patients in oncologic practice today.Predictions on the aging of the Spanish population showthat cancer in the aging patient and its treatment must be considereda first-line health problem. The diagnosis of cancer isnot associated with death in the majority of patients. Sixty percentof cancers are globally cured or chronified. This advancedprognosis has its toll not only in the expectancy of treatment butalso in subsequent follow-up and post-treatment adverse effectsthat can be generated.A greater and better knowledge and understanding of the agingprocess will allow to identify and select those old patientsthat can benefit from prevention and treatment options, andmore importantly will identify those other patients that are notcandidates to treatments with curative intention because of theirfrail status.Progress in surgery, mainly in minimally invasive surgery, andits application to the field of oncologic surgery allows to forecastthat a greater number of aging patients will benefit from treatmentwith curative intent. Age will not be a barrier for adequate treatmentin healthy elderly patients, especially in those with long lifeexpectancy and functional reserves. Fighting this healthcare discriminationis one of the main priorities in the strategy of improvedhealth in the elderlyWe present in this study and analyze the foreseen changes in theworld’s population, particularly in Spain; the association between cancer and age with its peculiar specificities; the general criteria forfrailty in older patients, the limitations that aging generate for adjuvanttreatments, and the new alternatives of treatment to be used inelderly oncologic patients for the most frequent tumors

Respuesta de autores: Réplica: Lesión iatrogénica de un conducto aberrante del sectorial anterior derecho hepático independiente. Dificultad en su diagnóstico y tratamiento / No disponible

No disponible

Lesión iatrogénica de un conducto aberrante del sectorial anterior derecho hepático (segmentos V-VIII) independiente. Dificultades en su diagnóstico y tratamiento / No disponible

No disponible

[Prevalence and treatment of oncologic disease in the elderly --an impeding challenge]. / Prevalencia y tratamiento de la patología oncológica en el anciano. El reto que se avecina.

Life expectancy in Spain has more than duplicated during the last 20th Century, and is currently 75 years for men and 83 years for women. Predictions on the evolution of the National and global population anticipate a demographic shock in Spain when individuals older than 65 years eventually make up more than 33.5% of the Spanish population by year 2050. It is known that cancer is directly related with age, and that it is a disease of older people -at least 60% of all cancers are diagnosed in patients older than 65 years. The older people group is the most important group of patients in oncologic practice today. Predictions on the aging of the Spanish population show that cancer in the aging patient and its treatment must be considered a first-line health problem. The diagnosis of cancer is not associated with death in the majority of patients. Sixty percent of cancers are globally cured or chronified. This advanced prognosis has its toll not only in the expectancy of treatment but also in subsequent follow-up and post-treatment adverse effects that can be generated. A greater and better knowledge and understanding of the aging process will allow to identify and select those old patients that can benefit from prevention and treatment options, and more importantly will identify those other patients that are not candidates to treatments with curative intention because of their frail status. Progress in surgery, mainly in minimally invasive surgery, and its application to the field of oncologic surgery allows to forecast that a greater number of aging patients will benefit from treatment with curative intent. Age will not be a barrier for adequate treatment in healthy elderly patients, especially in those with long life expectancy and functional reserves. Fighting this healthcare discrimination is one of the main priorities in the strategy of improved health in the elderly. We present in this study and analyze the foreseen changes in the world s population, particularly in Spain; the association between cancer and age with its peculiar specificities; the general criteria for frailty in older patients, the limitations that aging generate for adjuvant treatments, and the new alternatives of treatment to be used in elderly oncologic patients for the most frequent tumors.

Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update.

Colorectal cancer is the most frequent tumor of the digestive tract. The high incidence of abdominal dissemination; the poor prognosis of these patients, with median survival consistently ranging from 5 to 9 months in all studies of peritoneal carcinomatosis from colorectal cancer; the failure of adjuvant systemic chemotherapy treatment with a maximal survival of 18 months despite the development of new cytostatic drugs, and new combinations of use, make it crucial to search for and develop new treatment strategies. We review the principles of Sugarbaker s treatment protocol, which involves the combination of maximum cytoreductive radical oncological surgery for the treatment of all macroscopically disseminated disease with maximum perioperative intraperitoneal intensification chemotherapy to treat residual microscopic disease. We present the results of several scientific papers, all of them phase II studies with more than 10 patients treated, published in the medical literature by the main groups working in this line of treatment, together with the only phase III study reported and published so far, and finally the results of a recently reported retrospective international multicenter study. With this new alternative therapeutic approach, overall mean survival is 40% at 36 months, and 20% at 5 years. Based on these results, this new therapeutic approach is proposed as the treatment of choice for these unfortunate patients.

Carcinomatosis peritoneal de origen colorrectal. Estado actual del tratamiento. Revisión y puesta al día / Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update

El cáncer colorrectal es el tumor más frecuente del tracto digestivo.La alta incidencia de diseminación abdominal, el pobre pronósticode estos pacientes con una mediana de supervivencia entre5 y 9 meses demostrada repetidamente en todos los estudiosde carcinomatosis peritoneal por cáncer colorrectal, el fracaso delos tratamientos sistémicos adyuvantes con quimioterapia con supervivenciasmáximas de 18 meses independientemente del desarrollode nuevas drogas citostáticas y las nuevas combinaciones oformas de uso, hacen crucial la investigación y el desarrollo denuevas estrategias de tratamiento.Revisamos los principios del protocolo del tratamiento de Sugarbaker,que contempla la combinación de la máxima cirugía radicaloncológica citorreductora para el tratamiento de la enfermedadmacroscópica diseminada con la máxima quimioterapia deintensificación intraperitoneal perioperatoria para el tratamientode la enfermedad microscópica residual.Se presentan los resultados de las publicaciones científicas, detodos los estudios fase II con más de 10 pacientes tratados publicadosen la literatura médica por los principales grupos de trabajoen esta línea de tratamiento, junto con el único estudio fase III publicadohasta el momento, y finalmente los resultados de un recienteestudio multicéntrico internacional retrospectivo.Con esta nueva alternativa terapéutica, la supervivencia mediaa los 36 meses es del 40, y del 20% a los 5 años. Basados en estosresultados, proponemos esta alternativa de tratamiento comoel tratamiento de elección de estos desafortunados pacientes

Colorectal cancer is the most frequent tumor of the digestivetract. The high incidence of abdominal dissemination; the poorprognosis of these patients, with median survival consistentlyranging from 5 to 9 months in all studies of peritoneal carcinomatosisfrom colorectal cancer; the failure of adjuvant systemicchemotherapy treatment with a maximal survival of 18 monthsdespite the development of new cytostatic drugs, and new combinationsof use, make it crucial to search for and develop newtreatment strategies.We review the principles of Sugarbaker´s treatment protocol,which involves the combination of maximum cytoreductive radicaloncological surgery for the treatment of all macroscopically disseminateddisease with maximum perioperative intraperitoneal intensificationchemotherapy to treat residual microscopic disease.We present the results of several scientific papers, all of themphase II studies with more than 10 patients treated, published inthe medical literature by the main groups working in this line oftreatment, together with the only phase III study reported andpublished so far, and finally the results of a recently reported retrospectiveinternational multicenter study. With this new alternativetherapeutic approach, overall mean survival is 40% at 36months, and 20% at 5 years.Based on these results, this new therapeutic approach is proposedas the treatment of choice for these unfortunate patients

[Incidence of lymphoid neoplasms in patients with HIV infection]. / Incidencia de neoplasias linfoides en pacientes con infección por el HIV.

BACKGROUND: The incidence, histologic type and clinical characteristics of the lymphoid neoplasms found in patients with HIV infection may be influenced by environmental factors. These characteristics were herewith investigated in the authors medium. METHODS: The medical records of the patients in whom lymphoma was diagnosed were reviewed studying the usual clinical, epidemiological, histological and biological variables. RESULTS: Fourteen patients: 10 with non Hodgkin lymphomas and four with Hodgkin disease were studied. The prevalence was 5% of the total number of patients with AIDS. Seven patients of the former and none of the latter had previously uncomplicated HIV infection. The following histologic types were observed: two Burkitt lymphoma, 4 undifferentiated lymphomas and 4 immunoblastic lymphomas among the non Hodgkin cases and two with mixed cellularity, one lymphocytic depletion and one undetermined among the Hodgkin's cases. Eighty percent of the patients with non Hodgkin lymphoma and 50% of the patients with Hodgkin disease presented a IV-B stage. The median of survival was 2.5 months (limits 1-8) for non Hodgkin cases and 11 months (limits 1-36) for the patients with Hodgkin disease. CONCLUSIONS: The prevalence of lymphoma in patients with AIDS in the authors' medium is similar to that referred in other studies although a high proportion of Hodgkin's disease may be found.